Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ihsan Nijem
Pharmacokinetic and Exploratory Exposure–response Analysis of Pertuzumab in Patients With Operable HER2-positive Early Breast Cancer in the APHINITY Study
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study
Journal of Clinical Pharmacology
Pharmacology
Related publications
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn181 - Cost-Utility Analysis of Adjuvant Pertuzumab-Based Regimen in Women With Her2-Positive Breast Cancer in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
Optimal Treatment of Early Stage HER2-positive Breast Cancer
Cancer
Cancer Research
Oncology
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
International Journal of Breast Cancer
Cancer Research
Oncology
Pharmacology
Estimated Life-Years Saved in Women With HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
